AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 9356879 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole 40 mg i.v. bolus followed by 40 mg i.v. every 12 h for two days
Number of subjects: 52
Study 8146390 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 mg of mefloquine every month
Number of subjects: 122
Study 8146390 — intervention group
Group type: EXPERIMENTAL
Intervention: 250 mg of mefloquine every two weeks
Number of subjects: 122
Study 8146390 — intervention group
Group type: COMPARATOR
Intervention: 500 mg sulphadoxine + 25 mg pyrimethamine (Fansidar) a week
Number of subjects: 122
Study 8146390 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 122
Study 3524176 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined probucol (1 g/day) and colestipol (20 g/day)
Number of subjects: 71
Study 3524176 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified probucol-colestipol therapy (half-dose of colestipol)
Number of subjects: 71
Study 3524176 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined probucol-colestipol therapy after 1 and 3 years
Number of subjects: 71
Study 3524176 — intervention group
Group type: COMPARATOR
Intervention: Single-drug administration of probucol or colestipol
Number of subjects: 71
Study 30182113 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactoferrin (LF) supplementation, 3 tablets per day (250 mg per tablet) for 30 days
Number of subjects: 19
Study 26813357 — intervention group
Group type: EXPERIMENTAL
Intervention: ISA101 vaccination with 5% imiquimod at the vaccine site
Number of subjects: 43
Study 26813357 — intervention group
Group type: COMPARATOR
Intervention: ISA101 only
Number of subjects: 43
Study 24840349 — intervention group
Group type: EXPERIMENTAL
Intervention: Early detection and treatment by community health workers using rapid diagnostic technology
Number of subjects: 2884
Study 24840349 — intervention group
Group type: EXPERIMENTAL
Intervention: Community-supported larviciding
Number of subjects: 2884
Study 24840349 — intervention group
Group type: EXPERIMENTAL
Intervention: Early detection and treatment plus larviciding
Number of subjects: 2884
Study 24840349 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 2884
Study 23835590 — intervention group
Group type: COMPARATOR
Intervention: Intrathecal gabapentin 0 mg/day (placebo)
Number of subjects: 170
Study 23835590 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal gabapentin 1 mg/day
Number of subjects: 170
Study 23835590 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal gabapentin 6 mg/day
Number of subjects: 170
Study 23835590 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal gabapentin 30 mg/day
Number of subjects: 170
Study 23835590 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal gabapentin (all doses)
Number of subjects: 170
Study 23835590 — intervention group
Group type: EXPERIMENTAL
Intervention: Device-related adverse events
Number of subjects: 170
Study 20455960 — intervention group
Group type: EXPERIMENTAL
Intervention: Allogenic platelet gel
Number of subjects: 13
Study 20455960 — intervention group
Group type: COMPARATOR
Intervention: Current best practice approach to chronic wounds dressing protocol
Number of subjects: 13
Study 19065861 — intervention group
Group type: EXPERIMENTAL
Intervention: Kinaesthesis
Number of subjects: 0
Study 19065861 — intervention group
Group type: COMPARATOR
Intervention: Touch alone
Number of subjects: 0
Study 16169397 — intervention group
Group type: EXPERIMENTAL
Intervention: Long protocol
Number of subjects: 220
Study 16169397 — intervention group
Group type: COMPARATOR
Intervention: Short protocol
Number of subjects: 220
Study 12536327 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic fibrin glue injection
Number of subjects: 61
Study 12536327 — intervention group
Group type: COMPARATOR
Intervention: Early elective operation
Number of subjects: 61
Study 10645753 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 mg tacrolimus
Number of subjects: 18
Study 10645753 — intervention group
Group type: EXPERIMENTAL
Intervention: 7 mg tacrolimus
Number of subjects: 18
Study 10645753 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg tacrolimus
Number of subjects: 18
Study 8876707 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined androgen blockade (CAB) with zoladex 3.6 mg injection subcutaneous depot monthly and flutamide 250 mg orally three times per day for 2 months, followed by CAB with concurrent XRT (65-70 Gy) for 7-8 weeks
Number of subjects: 141
Study 8876707 — intervention group
Group type: EXPERIMENTAL
Intervention: Zoladex alone for 2 years (Z+ group)
Number of subjects: 141
Study 8876707 — intervention group
Group type: COMPARATOR
Intervention: No further treatment (Z- group)
Number of subjects: 141
Study 1543618 — intervention group
Group type: EXPERIMENTAL
Intervention: Temazepam elixir
Number of subjects: 15
Study 1543618 — intervention group
Group type: COMPARATOR
Intervention: Intravenous midazolam
Number of subjects: 15
Study 3892975 — intervention group
Group type: EXPERIMENTAL
Intervention: Tinidazole (one-shot prophylaxis)
Number of subjects: 100
Study 3892975 — intervention group
Group type: COMPARATOR
Intervention: Metronidazole (9 doses)
Number of subjects: 100
Study 31378628 — intervention group
Group type: COMPARATOR
Intervention: Morning chronotype
Number of subjects: 0
Study 31378628 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher TOTFA
Number of subjects: 0
Study 31378628 — intervention group
Group type: EXPERIMENTAL
Intervention: MUFA
Number of subjects: 0
Study 28899731 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical training
Number of subjects: 0
Study 28899731 — intervention group
Group type: EXPERIMENTAL
Intervention: Simultaneous physical-cognitive training
Number of subjects: 0
Study 25224018 — intervention group
Group type: EXPERIMENTAL
Intervention: PNHA (topical gel application two times a week for a total of 6 weeks)
Number of subjects: 39
Study 25224018 — intervention group
Group type: COMPARATOR
Intervention: HA (topical application)
Number of subjects: 39
Study 25224018 — intervention group
Group type: EXPERIMENTAL
Intervention: PNHA
Number of subjects: 39
Study 25224018 — intervention group
Group type: COMPARATOR
Intervention: HA
Number of subjects: 39
Study 24708617 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimal contact web-guided Cognitive Behavioral Therapy (CBT) intervention
Number of subjects: 339
Study 24708617 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobile-guided intervention comprising mindfulness, acceptance and value-based exercises
Number of subjects: 339
Study 24708617 — intervention group
Group type: EXPERIMENTAL
Intervention: Face-to-face group intervention using mindfulness, acceptance and value-based approach
Number of subjects: 339
Study 24708617 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 339
Study 22191856 — intervention group
Group type: EXPERIMENTAL
Intervention: Moxifloxacin punctum plug (MP)
Number of subjects: 20
Study 20005965 — intervention group
Group type: EXPERIMENTAL
Intervention: 1q21 gain
Number of subjects: 91
Study 20005965 — intervention group
Group type: COMPARATOR
Intervention: No 1q21 gain
Number of subjects: 91
Study 17997263 — intervention group
Group type: EXPERIMENTAL
Intervention: Counselling intervention with standard exercise and nutrition information plus up to five face-to-face counselling sessions with a Physical Activity Specialist (PAS) and Registered Dietitian (RD) over a 6-month period
Number of subjects: 334
Study 17997263 — intervention group
Group type: COMPARATOR
Intervention: Usual care (health promotion leaflet)
Number of subjects: 334
Study 16046715 — intervention group
Group type: EXPERIMENTAL
Intervention: High protein, reduced carbohydrates diet (1.6 g/(kg . d)) with supervised exercise (5 d/wk walking and 2 d/wk resistance training)
Number of subjects: 48
Study 16046715 — intervention group
Group type: EXPERIMENTAL
Intervention: Low protein, high carbohydrates diet (0.8 g/(kg . d)) with supervised exercise (5 d/wk walking and 2 d/wk resistance training)
Number of subjects: 48
Study 16046715 — intervention group
Group type: COMPARATOR
Intervention: High protein, reduced carbohydrates diet (1.6 g/(kg . d)) with lifestyle activity (control)
Number of subjects: 48
Study 16046715 — intervention group
Group type: COMPARATOR
Intervention: Low protein, high carbohydrates diet (0.8 g/(kg . d)) with lifestyle activity (control)
Number of subjects: 48
Study 12525339 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of stressful life events (SLE)
Number of subjects: 236
Study 12525339 — intervention group
Group type: COMPARATOR
Intervention: Control group (no SLE)
Number of subjects: 236
Study 10337449 — intervention group
Group type: EXPERIMENTAL
Intervention: Betaxolol
Number of subjects: 0
Study 10337449 — intervention group
Group type: COMPARATOR
Intervention: Carvedilol
Number of subjects: 0
Study 8954300 — intervention group
Group type: EXPERIMENTAL
Intervention: Left corona radiata infarcts
Number of subjects: 64
Study 8954300 — intervention group
Group type: COMPARATOR
Intervention: Right corona radiata infarcts
Number of subjects: 64
Study 8954300 — intervention group
Group type: EXPERIMENTAL
Intervention: Pontine base infarcts
Number of subjects: 64
Study 8954300 — intervention group
Group type: EXPERIMENTAL
Intervention: Dorsomedial portion of the pontine base lesions
Number of subjects: 64
Study 8954300 — intervention group
Group type: EXPERIMENTAL
Intervention: Ventromedial portion of the pontine base lesions
Number of subjects: 64
Study 1712803 — intervention group
Group type: EXPERIMENTAL
Intervention: Allergen challenge (single dose sprayed into one side of the nose)
Number of subjects: 9
Study 6227877 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of ipratropium bromide (40 micrograms/puff) and fenoterol (100 micrograms/puff)
Number of subjects: 12
Study 6227877 — intervention group
Group type: COMPARATOR
Intervention: Salbutamol (100 micrograms/puff)
Number of subjects: 12
Study 31602965 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol (Group TIVA)
Number of subjects: 90
Study 31602965 — intervention group
Group type: EXPERIMENTAL
Intervention: Desflurane (Group D)
Number of subjects: 90
Study 31602965 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane (Group S)
Number of subjects: 90
Study 29558848 — intervention group
Group type: EXPERIMENTAL
Intervention: Nail varnish applied
Number of subjects: 43
Study 29558848 — intervention group
Group type: COMPARATOR
Intervention: No nail varnish applied
Number of subjects: 43
Study 26909904 — intervention group
Group type: EXPERIMENTAL
Intervention: modified BLUPIS (BLUPISM) procedure
Number of subjects: 110
Study 26909904 — intervention group
Group type: COMPARATOR
Intervention: classic individuals (BLUPI)
Number of subjects: 110
Study 24560036 — intervention group
Group type: EXPERIMENTAL
Intervention: School-located vaccination program
Number of subjects: 3144
Study 23569986 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin chemotherapy (40-50 mg/day)
Number of subjects: 18
Study 19951955 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental adjuvant treatments
Number of subjects: 236
Study 19951955 — intervention group
Group type: COMPARATOR
Intervention: Control arms
Number of subjects: 236
Study 19951955 — intervention group
Group type: EXPERIMENTAL
Intervention: New treatments for metastatic disease
Number of subjects: 236
Study 17330176 — intervention group
Group type: EXPERIMENTAL
Intervention: Cholinesterase inhibitors (ChEI)
Number of subjects: 0
Study 17330176 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 17330176 — intervention group
Group type: EXPERIMENTAL
Intervention: Galantamine (a type of ChEI)
Number of subjects: 0
Study 15857723 — intervention group
Group type: EXPERIMENTAL
Intervention: Matrix Model (manualized treatment)
Number of subjects: 1016
Study 11856087 — intervention group
Group type: EXPERIMENTAL
Intervention: Synthetic human motilin (2 pmol x min/kg)
Number of subjects: 10
Study 11856087 — intervention group
Group type: EXPERIMENTAL
Intervention: Synthetic human motilin (4 pmol x min/kg)
Number of subjects: 10
Study 11856087 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 12569793 — intervention group
Group type: EXPERIMENTAL
Intervention: Chongcao shenkang capsules 2.7 grams tid
Number of subjects: 150
Study 12569793 — intervention group
Group type: COMPARATOR
Intervention: Control group (combined therapy with balanced salt solution and ribavirin)
Number of subjects: 150
Study 7475162 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant aprotinin (dosage level 1: 2 mg/kg bolus, 1 mg/kg in oxygenator prime, 0.5 mg/kg/hr infusion)
Number of subjects: 84
Study 7475162 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant aprotinin (dosage level 2: doubled doses)
Number of subjects: 84
Study 7475162 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant aprotinin
Number of subjects: 84
Study 7475162 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant aprotinin (dosage level 1)
Number of subjects: 84
Study 7475162 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant aprotinin (dosage level 2)
Number of subjects: 84
Study 7475162 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 84
Study 7475162 — intervention group
Group type: COMPARATOR
Intervention: Recombinant aprotinin and Control group
Number of subjects: 84
Study 2216190 — intervention group
Group type: EXPERIMENTAL
Intervention: Second-look laparotomy
Number of subjects: 131
Study 7002430 — intervention group
Group type: EXPERIMENTAL
Intervention: Bendroflumethiazide 10 mg daily for 3 days
Number of subjects: 0
Study 7002430 — intervention group
Group type: EXPERIMENTAL
Intervention: Bendroflumethiazide 10 mg daily for 10 weeks
Number of subjects: 0
Study 30596978 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous coronary intervention (PCI) with everolimus‐eluting stents
Number of subjects: 810
Study 30596978 — intervention group
Group type: COMPARATOR
Intervention: Coronary artery bypass grafting (CABG)
Number of subjects: 810
Study 30596978 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous coronary intervention (PCI)
Number of subjects: 810
Study 28060206 — intervention group
Group type: EXPERIMENTAL
Intervention: Acceptance and Commitment Therapy
Number of subjects: 129
Study 28060206 — intervention group
Group type: COMPARATOR
Intervention: Present Centered Therapy
Number of subjects: 129
Study 25756917 — intervention group
Group type: EXPERIMENTAL
Intervention: Ankle aspiration
Number of subjects: 0
Study 25756917 — intervention group
Group type: COMPARATOR
Intervention: Sham procedure
Number of subjects: 0
Study 23951362 — intervention group
Group type: EXPERIMENTAL
Intervention: RAL+DRV/r
Number of subjects: 58
Study 23951362 — intervention group
Group type: COMPARATOR
Intervention: LPV/r+TVD
Number of subjects: 58
Study 21353329 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol (2 to 2.5 mg/kg per day, divided in 3 doses)
Number of subjects: 20
Study 21353329 — intervention group
Group type: COMPARATOR
Intervention: Control group (historical controls)
Number of subjects: 20
Study 19378635 — intervention group
Group type: EXPERIMENTAL
Intervention: Crossing the border to purchase medications (US residents)
Number of subjects: 1000
Study 19378635 — intervention group
Group type: COMPARATOR
Intervention: Crossing the border to purchase medications (Ciudad Juarez residents)
Number of subjects: 1000
Study 19378635 — intervention group
Group type: EXPERIMENTAL
Intervention: Traveling to Mexico for dental care (US residents)
Number of subjects: 1000
Study 19378635 — intervention group
Group type: EXPERIMENTAL
Intervention: Traveling to Mexico for medical care (US residents)
Number of subjects: 1000
Study 19378635 — intervention group
Group type: COMPARATOR
Intervention: Traveling to the United States for medications or health care (Mexican nationals)
Number of subjects: 1000
Study 17544338 — intervention group
Group type: EXPERIMENTAL
Intervention: Cocaine experienced adults (CE)
Number of subjects: 17
Study 17544338 — intervention group
Group type: COMPARATOR
Intervention: Placebo (for CE)
Number of subjects: 17
Study 17544338 — intervention group
Group type: COMPARATOR
Intervention: Healthy normal volunteers (HN)
Number of subjects: 17
Study 15163331 — intervention group
Group type: EXPERIMENTAL
Intervention: Full dose hydrocortisone (10 mg twice daily)
Number of subjects: 10
Study 15163331 — intervention group
Group type: EXPERIMENTAL
Intervention: Half-dose hydrocortisone (5 mg twice daily)
Number of subjects: 10
Study 15163331 — intervention group
Group type: EXPERIMENTAL
Intervention: No treatment
Number of subjects: 10
Study 15163331 — intervention group
Group type: COMPARATOR
Intervention: Control (no glucocorticoid treatment)
Number of subjects: 10
Study 11798229 — intervention group
Group type: EXPERIMENTAL
Intervention: Around-the-clock (ATC) opioid therapy, specifically controlled-release oral formulations (e.g. morphine, oxycodone, hydromorphone, hydrocodone)
Number of subjects: 0
Study 11798229 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral administration of opioids
Number of subjects: 0
Study 9597370 — intervention group
Group type: EXPERIMENTAL
Intervention: Fig leaf decoction (FC)
Number of subjects: 10
Study 9597370 — intervention group
Group type: COMPARATOR
Intervention: Non-sweet commercial tea (TC)
Number of subjects: 10
Study 7930314 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral algorithm for dietary fat intake < or = 30% of energy
Number of subjects: 744
Study 3044723 — intervention group
Group type: EXPERIMENTAL
Intervention: Ajmaline (50‐75 mg i.v.)
Number of subjects: 31
Study 3044723 — intervention group
Group type: COMPARATOR
Intervention: Lidocaine (100‐200 mg i.v.)
Number of subjects: 31
Study 29294429 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal oxytocin (40 IU)
Number of subjects: 17
Study 29294429 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study 28019686 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary Inflammatory Index (DII)
Number of subjects: 160191
Study 25746151 — intervention group
Group type: EXPERIMENTAL
Intervention: Biocompatible solutions
Number of subjects: 185
Study 25746151 — intervention group
Group type: COMPARATOR
Intervention: Standard solutions
Number of subjects: 185
Study 25746151 — intervention group
Group type: EXPERIMENTAL
Intervention: Biocompatible solutions (sensitivity analysis)
Number of subjects: 185
Study 25746151 — intervention group
Group type: COMPARATOR
Intervention: Standard solutions (sensitivity analysis)
Number of subjects: 185
Study 25746151 — intervention group
Group type: EXPERIMENTAL
Intervention: Biocompatible solutions (economic terms)
Number of subjects: 185
Study 24277400 — intervention group
Group type: EXPERIMENTAL
Intervention: Enteral nutrition support (Ensure(R)) for 10 days before surgery
Number of subjects: 60
Study 24277400 — intervention group
Group type: COMPARATOR
Intervention: Isocaloric and isonitrogenous homogenized diet for 10 days before surgery
Number of subjects: 60
Study 24277400 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical observations (nausea and vomiting)
Number of subjects: 60
Study 21145052 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythromycin 125 mg intravenously 30 minutes before endoscopy
Number of subjects: 102
Study 21145052 — intervention group
Group type: COMPARATOR
Intervention: Placebo administered intravenously 30 minutes before endoscopy
Number of subjects: 102
Study 19011436 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine (4 mg)
Number of subjects: 22
Study 19011436 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study 17908562 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional Restoration Program (FRP) for 5 weeks at 25 hours/week
Number of subjects: 132
Study 17908562 — intervention group
Group type: COMPARATOR
Intervention: Active Individual Therapy (AIT) for 5 weeks at 3 hours/week
Number of subjects: 132
Study 17908562 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional Restoration Program (FRP)
Number of subjects: 132
Study 17908562 — intervention group
Group type: COMPARATOR
Intervention: Active Individual Therapy (AIT)
Number of subjects: 132
Study 15109089 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcranial electrostimulation
Number of subjects: 0
Study 15109089 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 11223449 — intervention group
Group type: EXPERIMENTAL
Intervention: Micronised fenofibrate (267 mg/day) for 12 months
Number of subjects: 11
Study 11223449 — intervention group
Group type: EXPERIMENTAL
Intervention: Micronised fenofibrate (267 mg/day) for 3 months
Number of subjects: 11
Study 11223449 — intervention group
Group type: COMPARATOR
Intervention: VLDL-1 (100 microg apoB/ml)
Number of subjects: 11
Study 11223449 — intervention group
Group type: COMPARATOR
Intervention: VLDL-1 vs VLDL-2 at 100 microg apoB/ml
Number of subjects: 11
Study 11223449 — intervention group
Group type: COMPARATOR
Intervention: VLDL-1 vs IDL at 100 microg apoB/ml
Number of subjects: 11
Study 11223449 — intervention group
Group type: EXPERIMENTAL
Intervention: Micronised fenofibrate (267 mg/day)
Number of subjects: 11
Study 9326751 — intervention group
Group type: EXPERIMENTAL
Intervention: Physostigmine
Number of subjects: 45
Study 9326751 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45
Study 7955804 — intervention group
Group type: EXPERIMENTAL
Intervention: Zolpidem (0.21 mg/kg)
Number of subjects: 9
Study 7955804 — intervention group
Group type: EXPERIMENTAL
Intervention: Flumazenil (0.04 mg/kg)
Number of subjects: 9
Study 7955804 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study 3296982 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin therapy withdrawn
Number of subjects: 49
Study 3296982 — intervention group
Group type: COMPARATOR
Intervention: Control (diet and diabetes education without insulin withdrawal)
Number of subjects: 49
Study 3296982 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin-withdrawal patients
Number of subjects: 49
Study 3296982 — intervention group
Group type: COMPARATOR
Intervention: Control patients
Number of subjects: 49
Study 3296982 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin therapy
Number of subjects: 49
Study 29726050 — intervention group
Group type: EXPERIMENTAL
Intervention: Booklet containing dietary advice
Number of subjects: 492
Study 29726050 — intervention group
Group type: EXPERIMENTAL
Intervention: Booklet containing dietary advice plus tailored telephone intervention
Number of subjects: 492
Study 29726050 — intervention group
Group type: COMPARATOR
Intervention: Usual care (Control group)
Number of subjects: 492
Study 27716696 — intervention group
Group type: EXPERIMENTAL
Intervention: Enriched breast milk feed (EBM + energy supplementation/fortification with human milk fortifier and Simyl medium‐chain triglyceride oil)
Number of subjects: 50
Study 27716696 — intervention group
Group type: COMPARATOR
Intervention: Expressed breast milk (EBM; 0.65 kcal/ml)
Number of subjects: 50